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Summary 23 
Obesity is the most common cause of metabolic complications and poor quality of life in 24 
Prader-Willi syndrome (PWS). Hyperphagia and obesity develop after an initial phase of 25 
poor feeding and failure to thrive. Several mechanisms for the aetiology of obesity in PWS 26 
are proposed which include disruption in hypothalamic pathways of satiety control resulting 27 
in hyperphagia, aberration in hormones regulating food intake, reduced energy expenditure 28 
due to hypotonia and altered behaviour with features of autism spectrum disorder. Profound 29 
muscular hypotonia prevents PWS patients from becoming physically active, causing reduced 30 
muscle movements and hence reduced energy expenditure. In a quest for the aetiology of 31 
obesity, recent evidence has focused on several appetite-regulating hormones, growth 32 
hormone, thyroid hormones and plasma adipocytokines. However, despite advancement in 33 
understanding of the genetic basis of PWS, there are contradictory data on the role of satiety 34 
hormones in hyperphagia and data regarding dietary intake are limited. Mechanistic studies 35 
on the aetiology of obesity and its relationship with disease pathogenesis in PWS are 36 
required. . In this review, we focused on the available evidence regarding mechanisms of 37 
obesity and potential new areas that could be explored to help unravel obesity pathogenesis in 38 
PWS.   39 
  40 
  41 
Page 2 of 50Pediatric Obesity
3 
 
Introduction 42 
Prader-Willi Syndrome (PWS) is a genetic neurological disorder due to loss of function in the 43 
long arm (q11-q13) of paternally derived chromosome 15 occurring in 1 in 16,000 (1 in 44 
10,000 to 1 in 25,000) live births. The loss of function can be caused by a deletion in 45 
chromosome 15 (~70-75%), uniparental disomy (UPD) (~20-25%), an imprinting defect due 46 
to a mutation in the imprinting centre of the chromosome 15 (~2-5%) or unbalanced 47 
translocations (~1%) (1, 2). 48 
The syndrome is characterised prenatally by decreased fetal movements, 49 
polyhydromnios and post-natally by hypotonia (“floppy child”), feeding problems, and 50 
failure to thrive in early infancy, followed by growth delay, learning difficulties, hyperphagia 51 
and obesity, sleep abnormalities, behavioural problems and hypogonadism (1). Characteristic 52 
phenotypic features in most but not all PWS patients include short stature, small hands and 53 
feet, narrow nasal bridge, almond shaped palpebral fissures, thin upper lip, narrow bifrontal 54 
diameter, scoliosis, eye abnormalities, thick saliva, and hypopigmentation (1). 55 
Severe obesity develops in various nutritional stages (3). A classical description of 56 
these stages was based on two phases; poor feeding, hypotonia, and failure to thrive in early 57 
infancy (phase 1, 0-9 months age), followed by hyperphagia leading to obesity (phase 2, >9 58 
months age to adulthood). However, in a large cohort study of PWS patients followed for 10 59 
years, Miller et al. observed a more gradual shift occurring over 7 nutritional phases starting 60 
from before birth (phase 0) and continuing into childhood (phase 1a, 1b, 2a, 2b, 3) and adult 61 
life (phase 4) (3). These were based on the child’s food intake, behaviour, and growth in body 62 
mass (Figure 1).  63 
Although Prader Willi syndrome is the most common cause of syndromal obesity, a 64 
major cause of metabolic complications and mortality in this group (4), the exact mechanism 65 
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for the development of obesity is still largely unknown. Abnormalities in the hypothalamic 66 
satiety centre and its hormonal circuitry have been suggested to affect energy expenditure (5), 67 
food intake (2), and hormonal deficiencies (2). Other factors implicated include muscle tone 68 
(6) and body composition (7). Scoliosis in PWS patients with increasing age is proposed to be 69 
the result of prolonged hypotonicity, increasing age, obesity and subtle bone dysplasia rather 70 
than growth hormone therapy.  However, the interaction of these factors is complex and 71 
needs further study. Furthermore, controversial data on the role of satiety hormones, insulin, 72 
and plasma adipocytokines suggest that other unknown mechanisms may play a role in the 73 
aetiology of obesity in PWS. How far the occurrence of obesity in itself is a confounding risk 74 
factor for the distribution of fat and lean mass rather than hormonal aberrations remains to be 75 
determined. Diet is an important contributor to the onset and progression of obesity however 76 
there are very few studies looking at the dietary intake of PWS patients. This review explores 77 
recent evidence related to the hormonal, dietary, and body composition factors related to 78 
obesity in PWS. Furthermore, it also suggests potential new areas of research that may help 79 
unravel obesity pathogenesis in PWS. 80 
Hormonal hypothalamic regulation of satiety 81 
Several hormones related to central and hypothalamic satiety signals have been studied to 82 
explain the aetiology of obesity in PWS (Table 1). Functional magnetic resonance imaging 83 
data suggest that PWS patients show greater post-meal sub-cortical (hypothalamus, 84 
amygdala, hippocampus) stimulation of food activation centres in the limbic and paralimbic 85 
region compared to non-PWS obese and healthy lean controls. In contrast, simple obesity is 86 
associated with significantly higher activity in the dorsolateral prefrontal and orbitofrontal 87 
cortex associated with inhibitory control of food intake compared to PWS patients (8). This 88 
response is even higher for high versus low calorie foods as studies also suggest hyper-89 
stimulation of the satiety related hypothalamic neuronal circuitry in PWS patients compared 90 
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to non-PWS obese patients in response to high calorie vs. low calorie foods (9). This 91 
indicates that functional dysfunction of reward circuitry regions associated with 92 
hypothalamic-satiety-regulating hormones is also involved in development and maintenance 93 
of obesity in PWS.  94 
Ghrelin 95 
Ghrelin is a gut hormone which stimulates food intake (orexogenic),  growth hormone 96 
release, gastric emptying, regulates glucose metabolism, stimulates adipose tissue 97 
lipogenesis, and inhibits lipid oxidation (10). Elevated levels of plasma ghrelin stimulate 98 
agouti related peptide (AGRP) neurons in the arcuate nucleus of the hypothalamus which in 99 
turn inhibit the melanocortin receptor 4 (MCR4) in the paraventricular nucleus of 100 
hypothalamus. Inhibition of MCR4 results in delayed satiety and loss of appetite. Persistently 101 
increased orexigenic ghrelin levels in PWS, particularly in children after 3-5 years age 102 
compared with normal children were first reported by DelParigi and colleagues (11) 103 
supported by other studies comparing PWS patients with non-PWS obese, healthy lean, leptin 104 
deficient, and melatonin receptor 4 deficient patients (12, 13, 14). In their study, ghrelin 105 
levels remained high in PWS patients compared to healthy controls even after the same 106 
satiating dose of liquid meals which led to a delayed sense of fullness and persistent drive to 107 
eat (11) (Figure 2). 108 
However in contrast, others found no significant difference in plasma ghrelin levels 109 
between normal weight PWS patients less than 5 years of age, compared with healthy 110 
children matched for age, BMI, and gender (15). This may indicate that levels of ghrelin in 111 
PWS patients increase in childhood only prior to the onset of obesity which does not occur in 112 
healthy children. This assertion is supported by a study which showed significantly higher 113 
levels of plasma ghrelin and a negative correlation between plasma total ghrelin levels and 114 
BMI SDS in lean PWS children (median age 3.6 years) compared to lean controls (16). In a 115 
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recent study of sixty very young (<2 years age) PWS patients in the early nutritional phase 116 
(phase 1), plasma ghrelin levels were significantly higher than in healthy early-onset 117 
morbidly obese patients and healthy sibling lean controls (17). Higher levels of ghrelin were 118 
observed in these patients in early nutritional phases (phase 1a and 1b) long before the onset 119 
of hyperphagia which suggests that higher plasma ghrelin may not be causally related to the 120 
onset of hyperphagia (17). Ghrelin up-regulates adipose tissue lipogenesis and inhibits 121 
lipolysis by activating sterol response element binding proteins, acyl CoA carboxylase, 122 
lipoprotein lipase, and fatty acid synthase independent of its orexigenic effects (18). Whether 123 
persistent increases in plasma ghrelin are involved in triggering higher fat mass in PWS and 124 
whether the effect of growth hormone on fat mass is due to suppression of the plasma ghrelin; 125 
needs further research.  126 
 127 
Insulin 128 
Plasma insulin deficient states or insulin resistance cause diabetes mellitus, and up to 20% of 129 
PWS children develop type 2 diabetes (19). Insulin inhibits neuropeptide Y and stimulates 130 
pro-opiomelanocortin (POMC) neurons in the arcuate nucleus to reduce food intake and is 131 
regarded as one of the mechanisms contributing to obesity in PWS. Some evidence suggests 132 
lower fasting plasma insulin and delayed insulin secretion during an oral glucose tolerance 133 
test (OGTT) with or without normal insulin sensitivity (20), while others have suggested 134 
increased plasma insulin depicting insulin resistance (21) (Table 1). When compared with 135 
age, weight, and BMI matched non-PWS obese controls, obese PWS subjects manifest 136 
different glucoregulatory mechanisms via reduced β-cell response to glucose stimulation, a 137 
significantly increased hepatic insulin extraction, and dissociation of obesity and insulin 138 
resistance (22). Obesity is a diabetogenic state, therefore it is unclear whether changes in 139 
insulin levels are a consequence of severe obesity or the insulin secreting capability of PWS 140 
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patients is abnormal (20). Plasma insulin is an inhibitor of ghrelin independent of plasma 141 
glucose levels (23). Reduced insulin levels in diabetic PWS patients may therefore be a 142 
contributory factor to the elevated plasma ghrelin and its hypothalamic effects.  143 
Growth hormone 144 
Deficiency of growth hormone (GH) in PWS is associated with low muscle mass, increased 145 
fat mass, poor muscle tone and strength, decreased movements, and reduced energy 146 
expenditure and exercise tolerance (24). GH replacement therapy in adult PWS patients is 147 
associated with an increase in skeletal muscle mass, reduction in percentage body fat, 148 
increased muscle tone and exercise endurance, independent of the growth hormone secretory 149 
status (25). Furthermore, higher systemic inflammatory cytokines such as TNFα, MCP-1, and 150 
IL-8 and significantly lower fasting glycaemia, insulinemia, IGF-1, and HOMA-IR values 151 
have been shown to partially reverse with GH replacement therapy compared to non-PWS 152 
obese controls.  Compared to untreated patients Tanner stage 1 and 2, GH replacement 153 
therapy seems to improve mean energy intake and reduce total body fat mass measured by 154 
DEXA despite higher saturated fat intake (26). This might indicate improved metabolism and 155 
energy expenditure with GH treatment. Moreover, studies following patients for 12-24 156 
months after the cessation of GH replacement have shown a progressive increase in BMI and 157 
a tendency towards an increase in visceral adipose tissue (27). 158 
Obestatin 159 
Obestatin is produced in the stomach by post-translational modification of ghrelin. In contrast 160 
to ghrelin, obestatin suppress food intake, inhibits gastric emptying, and decrease weight gain 161 
(28). Unlike ghrelin, obestatin binds to a G protein coupled receptor 39 (GPR39) although it 162 
does not cross the blood brain barrier (28). No study has reported significant difference in 163 
plasma obestatin levels between obese PWS and obese non-PWS patients (29). 164 
Plasma Adipocytokines 165 
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Leptin 166 
Leptin reduces food intake and energy metabolism by inhibiting neuropeptide Y neurons in 167 
the arcuate nucleus. Although plasma leptin in PWS patients is positively correlated with 168 
BMI and body fat mass, no difference has been found in leptin concentration in PWS infants 169 
(17), children and adults (30) compared to healthy normal weight and obese when adjusted 170 
for BMI or fat mass. Although, significantly higher leptin mRNA and plasma leptin 171 
concentration in obese PWS and non-PWS obese children compared to healthy non-obese 172 
children was also reported in a small number of patients (n=6 in each group) (31). No 173 
difference in the relationship of leptin mRNA levels between PWS and non-PWS obesity 174 
might suggest similar response of leptin to obesity regardless of its cause. Whether the 175 
hypothalamic response to the levels of leptin is also the same, needs to be investigated. 176 
Amongst other adipocytokines, plasma resistin and adiponectin have been studied in 177 
PWS obese and non-obese patients (32, 33) (Table 1).  Higher levels of resistin are associated 178 
with insulin resistance and lipogenesis in PWS obese patients (32) while plasma adiponectin 179 
is anti-inflammatory, anti-atherogenic and associated with increased insulin sensitivity in 180 
PWS patients (33). 181 
Visfatin, produced by adipose tissue, is positively associated with systemic 182 
inflammation, atherogenesis, and diabetes (34) and increases by up to 32% for each hour 183 
decrease in rapid eye movement (REM) sleep (35). PWS patients with obesity have reduced 184 
REM sleep and are therefore at risk of increased plasma adipocytokines. However, visfatin 185 
has not yet been measured in PWS. 186 
Peptide YY 187 
Peptide YY is released from ileal and colonic cells postprandially to induce satiety by 188 
stimulating POMC neurons, inhibiting NPY, and reducing gastric emptying (Table 1, Figure 189 
2). There are two isoforms; PYY (1-36), selective for NPY1, 2, and 5 receptors, and PYY (3-190 
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36), an anorectic sub-type, highly selective for NPY2 receptor in the arcuate nucleus which 191 
regulates food intake under physiological conditions (36). There is contradictory evidence 192 
suggesting reduced (14) or increased (37) levels of PYY (3-36) in obese PWS compared to 193 
non-PWS obese and lean controls. 194 
Thyroid hormones 195 
Approximately 20-30 % of PWS patients suffer from deficiency in central hypothalamic 196 
thyroid hormone-releasing hormone at birth  (1, 38) and up to 2 years of age (38). Reduced 197 
free, total T4, T3, and TSH suggests disturbance of the hypothalamic thyroid-releasing 198 
hormone and TSH axis. Hypothyroidism from early infancy adds to the floppiness, 199 
hypotonia, reduced energy expenditure and reduced BMR and hence obesity in later years. 200 
 201 
In summary, alteration in several satiety and peripheral satiety hormones may affect the 202 
hypothalamic satiety regulation in PWS resulting in delayed satiety and early appetite 203 
stimulation (Table 1). Furthermore, the peripheral effects of growth and thyroid hormone 204 
deficiency affect body composition contributing to reduced energy expenditure. 205 
Contradictory data on the relationship of body fat mass and BMI in PWS and non-PWS obese 206 
patients raises the question as to whether satiety hormones are causatively related to the 207 
aetiology of hyperphagia in PWS.   208 
Dietary intake in PWS 209 
Obesity results from an imbalance between energy intake and expenditure. Diet is therefore 210 
likely to be an important contributory factor. Although reduced energy expenditure and 211 
hypothalamic dysfunction might promote energy accumulation in PWS children and young 212 
adults, the occurrence of in-satiable hunger and gastroparesis might promote dietary intake 213 
(39). “Hypo-activity” and “hypo-metabolism” in PWS children requires intake of 20-30% 214 
lower energy than healthy age-matched children. Adherence to specific macronutrient and 215 
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energy restricted diets reduces the proportion of body fat (19.8% vs. 41.9%) and body mass 216 
index (0.3 SDS vs. 2.23 SDS) in children and adults (40).   217 
Although the effect of dietary intervention on the body composition of PWS patients 218 
has been investigated, very few studies have looked at actual daily dietary intake in obese 219 
PWS children. Furthermore, none has compared dietary intake between healthy obese and 220 
obese-PWS groups of the same age range which could give an indication whether PWS obese 221 
patients under-report or under-eat similar to the healthy obese.  222 
An early study by Holm and Pipes (1976) on 14 PWS patients reported an intake of 223 
650-1050 Kcal/day during the initial period of weight loss depending on the size of the 224 
patient (41). Eight of 11 patients who lost weight were able to successfully maintain their 225 
weight over 6 months to 5 years on a 800-1990 Kcal/day diet appropriate for age (41). This 226 
suggests that hyperphagia and subsequent obesity can be prevented by restriction of caloric 227 
intake. Moreover, children below 5 years with PWS report a daily energy intake of 228 
approximately 30% to 65% below recommended amounts followed for up to 3 years (42). 229 
Similar results have been observed in adults with reported daily energy intake of 1000-1500 230 
kcal (43).  231 
These studies are limited by subject numbers, narrow age range, limited time of 232 
dietary data collection, not accounting for age related differences in dietary intake, and 233 
dietary intake reported by parents. Recording reliable dietary information in PWS patients 234 
with behavioural issues is a challenge. Intake of a balanced nutritious diet is essential for 235 
normal growth and homeostasis. This suggests consideration of appropriate nutritional 236 
support tailored to individuals and not just energy restriction. Further large scale studies with 237 
more robust methods of recording dietary data are needed to record the routine nutrient intake 238 
of these patients before dietary intervention strategy is applied to ensure balanced growth, 239 
preventing obesity and under-nutrition of the patients at the same time.  240 
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Body composition in PWS 241 
Obesity attributed to no known identifiable cause has been shown to differ from 242 
hypothalamic obesity in PWS in terms of both intrinsic (such as GH, thyroid hormones, 243 
insulin, and leptin) and extrinsic factors (such as exercise, diet, and lifestyle). Growth 244 
hormone deficiency, hypothyroidism and hypogonadism in addition to lower energy 245 
expenditure (both resting and activity), hypotonia, and behavioural issues in patients with 246 
PWS result in lower lean mass by 25-27% and a higher fat mass compared to simple obese 247 
patients (44). Reduced lean mass with lower physical activity and muscular hypotonia could 248 
result in less weight-bearing stress on the bones and hence lower bone-mineral content and 249 
density (45) particularly after adjustment for height and age of the patient. This suggests that 250 
differences in lean mass, fat mass or bone-mineral density should also be studied in the 251 
context of height for age of the patients and their pituitary status. The distribution of fat and 252 
lean mass differ between body sites (e.g. between lumber & spine area and the hips & thighs) 253 
indicates the need for careful interpretation of body composition measurements. How far the 254 
occurrence of obesity in itself is a confounding risk factor for fat and lean mass distribution 255 
rather than hormonal aberrations, remains to be determined. Long-term follow up studies are 256 
therefore required to characterize the changes in body composition in PWS patients. 257 
Genetic variants in relation to obesity in PWS 258 
Of the three main molecular mechanisms of PWS genotypes (deletion, UPD 15, and 259 
imprinting defects), no significant difference in the prevalence of obesity or hyperphagia 260 
between the deletion or non-deletion PWS patients have been reported (46). Although no 261 
peculiar characteristic can exclusively be attributed to individual genotype, psychiatric illness 262 
and intellectual disability is more common in mUPD compared to need for special feeding 263 
techniques, sleep disturbance, hypopigmentation, and speech articulation defects in the 264 
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deletion group (47). Although individual cases have been reported suggesting association of 265 
hyperphagia, obesity and hypogonadism with specific genetic aberrations such as 266 
microdeletions of HBII-85 class of small nucleolar RNAs (snoRNAs) (48), lack of expression 267 
of PWCR1/HBII-85 snoRNAs (49), and SNORD116 C/D box snoRNA cluster (50), there is 268 
scarcity of mechanistic evidence from mutant animal models that could prove the effect of 269 
these aberrations on obese/lean phenotype. 270 
Patients with UPD have been observed with significantly lower insulin-induced growth 271 
hormone secretion compared to the deletion group (51). However there was no significant 272 
difference in the yearly improvement in height (52) or the bone-mineral density (53) in 273 
response to GH replacement therapy in either group. The lack of significant obese phenotype-274 
genotype correlation and a similar response to GH despite differences in basal GH secretion 275 
suggests that PWS children acquire obesity regardless of the genetic cause and that obesity 276 
results from a constellation of behavioral, psychiatric, and developmental disturbances.  277 
Physical activity and behaviour in PWS 278 
With characteristic disease-related muscle hypotonia and alteration in body composition, 279 
differences in physical activity between obese PWS and obese non-PWS patients or the 280 
healthy population are expected. Evidence suggests reduced physical activity (by ~20%) and 281 
reduced vigour (by ~30%) in PWS obese versus non-PWS obese subjects (6). Only 12% 282 
patients reach local recommendations for daily physical activity compared with 20-22% of 283 
the normal population (54). Interestingly, this physical activity level is independent of 284 
adiposity.  285 
Long term home based exercise interventions improve lean muscle mass, reduce calf skinfold 286 
and increase spontaneous physical activity (from 45% to 71%), and exercise capacity (from 287 
31% to 78%) (55). 288 
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Autistic features are present in up to 36% PWS patients and could be due to the 289 
overexpression of ubiquitin protein ligase E3A (UBE3A) in maternal UPD, which 290 
significantly contributes to mental retardation and behavioural and communication problems 291 
(56). These traits tend to increase with age (56) and may contribute to overweight and obesity 292 
by increasing dietary intake and reduce physical activity due to a “lonely” and less socializing 293 
behaviour.  294 
Patients with PWS frequently suffer from daytime sleepiness and have abnormal 295 
circadian rhythms of rapid eye movement sleep, central hypoventilation, abnormal 296 
ventillatory response to hypoxia, and hypercapnia. This leads to episodes of apnoea and 297 
hypopnea and disturbed sleep further exacerbated by obesity. Constellation of these disorders 298 
lead to reduced physical activity and energy expenditure, anxiety, stereotyped behaviour, 299 
difficulty in maintaining social relations and communication (57). 300 
Conclusions and future directions 301 
Obesity is the leading cause of morbidity and mortality in PWS patients. It is a complex 302 
phenomenon occurring due to disturbance in the hypothalamic satiety regulatory mechanisms 303 
contributed by several hormones, body composition differences, low physical activity, altered 304 
feeding behaviour and increased dietary intake (supplementary figure 1). However, the exact 305 
mechanisms responsible remain to be determined and need further study. 306 
Obesity in PWS is associated with chronic low-grade inflammation which is not 307 
explained by obesity and insulin resistance (58). The gut microbiota have been recently 308 
suggested to be involved in obesity-genesis via increased energy harvest from fermentable 309 
carbohydrates. The gut microbiota in non-PWS obesity have also been associated with 310 
chronic low-grade inflammation. However, this has not been studied in obese PWS patients. 311 
There is limited evidence of baseline dietary habits of PWS patients and therefore 312 
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longitudinal studies are needed to elucidate the dietary patterns of these patients to 313 
individually tailor dietary intervention. 314 
 315 
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Figure Legends 323 
 324 
Figure 1: Obesity in relation to nutritional phases in Prader-Willi syndrome. 325 
PWS children are hypotonic with poor suck and failure to thrive in early infancy but 326 
gradually catch up with their growth in phase 2a and 2b. Obesity develops by phase 3 when 327 
most of the factors contributing to obesity have already set in. Some patients develop obesity 328 
very early (e.g. during phase 2a) (Miller et al 2011) (course shown in dotted line). NIDDM; 329 
Non-insulin dependent diabetes mellitus, m; months, y; years 330 
 331 
Figure 2: Mechanism of obesity in Prader Willi Syndrome. Adapted from Mutch 332 
and Karine (2006) (59). 333 
Decreased plasma insulin and PYY result in loss of stimulatory signals to the POMC neurons 334 
and loss of inhibitory signals to NPY neurons in the arcuate nucleus which fails to stimulate α 335 
and β-MSH to control satiety via activation of MCR4 receptor in the Paraventricular nucleus. 336 
The role of leptin is still under investigation (marked with “?” in the figure) as overall 337 
evidence suggests no difference in leptin concentration in PWS obese vs. non-PWS obese. 338 
On the other hand, persistent increase in plasma ghrelin results in stimulation of neurons 339 
expressing NPY and AGRP which inhibit MCR4 signalling and hence increase drive towards 340 
food intake (3). Alteration in TRH-TSH axis results in reduced energy expenditure (2). 341 
Deficiency of GH due to loss of feedback mechanism despite persistent increase in plasma 342 
ghrelin results in growth delay increasing weight for height ratio, reduced muscle mass, and 343 
increased body fat (1). AGRP, agouti-related protein; α-MSH, alpha melanocyte stimulating 344 
hormone receptor; NPY, neuropeptide Y; POMC, pro-opiomelanocortin;TRKB, tyrosine 345 
kinase receptor, GH; growth hormone, PYY; Peptide YY, TRH; Thyroid hormone releasing 346 
hormone, TSH; Thyroid stimulating hormone, TRKB; Tyrosine kinase receptor B.  347 
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 348 
Supplementary figure 1: Simplified scheme for the mechanism of obesity in 349 
Prader Willi syndrome 350 
GH; Growth hormone, TSH-TRH; thyroid stimulating hormone-thyroid releasing hormone, 351 
EE; energy expenditure, BMR; basal metabolic rate 352 
  353 
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Table 1: Hormones related to aetiology of obesity in Prader-Willi Syndrome 354 
Hormone Site of 
Production 
Site of Action Physiological Role Pathology in PWS Ref 
Ghrelin Stomach AGRP in Arcuate 
nucleus, adipose 
tissues 
Regulates short term food intake, 
↑ in hunger, ↓ after food intake,  
Persistently ↑ ghrelin even after food 
intake leading to weight gain. Levels 
vary with age 
(11) 
   Regulates lipid metabolism ↑ body fat   
   ↑ GH secretion Failure to increase GH leading to 
growth delay, failure to thrive, short 
stature 
 
Obestatin Derived post-
transnationally 
from 
preproghrelin 
AGRP in Arcuate 
nucleus 
Suppresses appetite, inhibit 
jejunal contractions, and decrease 
body weight 
Limited evidence, Higher Obestatin in 
≤3 years PWS patients contributing to 
failure to thrive and poor feeding in 
early stages 
(60) 
    No difference between obese PWS and 
obese controls 
(29) 
Leptin Adipose tissue POMC and NPY 
neurons in arcuate 
nucleus 
Primarily inhibits NPY but also 
stimulates POMC neurons leading 
to stimulation of MCR4 receptor 
to induce satiety 
Levels similar in PWS and obese 
control although positively correlated 
with BMI and body fat 
(30) 
Resistin Adipose tissue Liver Hepatic insulin resistance and 
lipogenesis 
↑ in PWS (not related to insulin 
resistance, only related to the degree of 
(32) 
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obesity) 
    No difference between obese PWS and 
obese and lean controls 
(33) 
Adiponectin Adipose tissue β-cells in pancreas ↑ Insulin sensitivity , anti-
inflammatory,  anti-atherogenic 
↑ in PWS compared to non-PWS obese, 
significant positive correlation with 
insulin sensitivity in PWS but not in 
obese controls 
(33) 
    ↑ in PWS compared to obese controls 
but ↓ in PWS compared to lean, no 
correlation with insulin sensitivity and 
anthropometric measurements 
(37) 
Visfatin Adipose tissue Pancreas, muscles, 
liver 
Associated with inflammation and 
insulin resistance. Increase with 
short sleep duration 
No data available  
PYY Duodenum Inhibitory 
Presynaptic receptor 
for NPY 
Induce satiety by stimulating 
POMC and inhibiting NPY 
resulting in dis-inhibition of α and 
β MSH 
↓ PYY (3-36) in PWS compared to 
healthy controls leading to delayed 
sense of fullness 
(14) 
   Reduce gastric emptying and gut 
transit time 
Delayed sense of fullness, overeating   
    ↑ in PWS compared to non-PWS obese, (61) 
    ↑ in PWS compared to obese controls 
but ↓ in PWS compared to lean. No 
(37) 
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GLP-1; Glucagon-like peptide 1, AGRP; Agouti-related peptide, GH; growth hormone,  POMC; pro-opiomelanocortin, NPY; neuropeptide Y, 355 
NIDDM; non-insulin dependent diabetes mellitus,  PWS; Prader-Willi syndrome. 356 
correlation with insulin sensitivity and 
anthropometric measurements 
Insulin Pancreas POMC and NPY 
neurons in arcuate 
nucleus 
Stimulate POMC and inhibit NPY 
neurons leading to stimulation of 
MCR4 receptor to induce satiety 
↓ in PWS leading to hyperphagia, and 
NIDDM in adulthood 
(61) 
Growth 
Hormone 
Anterior 
pituitary 
Muscles, Bones, 
adipose tissue 
Induces normal growth and 
energy metabolism 
Growth delay, altered metabolism and 
energy expenditure 
(24, 25) 
GLP-1 Intestine Pancreas Enhances insulin sensitivity  No difference at baseline, ↑ after GH 
replacement therapy 
(33) 
Thyroid 
hormones 
Thyroid gland Muscles, Bones, 
adipose tissue 
Regulate whole body metabolism ↓ in PWS resulting in altered metabolic 
rate and energy expenditure 
(38) 
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Table 1: Hormones related to aetiology of obesity in Prader-Willi Syndrome 
Hormone Site of 
Production 
Site of Action Physiological Role Pathology in PWS Ref 
Ghrelin Stomach AGRP in Arcuate 
nucleus, adipose 
tissues 
Regulates short term food intake, 
↑ in hunger, ↓ after food intake,  
Persistently ↑ ghrelin even after food 
intake leading to weight gain. Levels 
vary with age 
(11) 
   Regulates lipid metabolism ↑ body fat   
   ↑ GH secretion Failure to increase GH leading to 
growth delay, failure to thrive, short 
stature 
 
Obestatin Derived post-
transnationally 
from 
preproghrelin 
AGRP in Arcuate 
nucleus 
Suppresses appetite, inhibit 
jejunal contractions, and decrease 
body weight 
Limited evidence, Higher Obestatin in 
≤3 years PWS patients contributing to 
failure to thrive and poor feeding in 
early stages 
(60) 
    No difference between obese PWS and 
obese controls 
(29) 
Leptin Adipose tissue POMC and NPY 
neurons in arcuate 
nucleus 
Primarily inhibits NPY but also 
stimulates POMC neurons leading 
to stimulation of MCR4 receptor 
to induce satiety 
Levels similar in PWS and obese 
control although positively correlated 
with BMI and body fat 
(30) 
Resistin Adipose tissue Liver Hepatic insulin resistance and 
lipogenesis 
↑ in PWS (not related to insulin 
resistance, only related to the degree of 
obesity) 
(32) 
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    No difference between obese PWS and 
obese and lean controls 
(33) 
Adiponectin Adipose tissue β-cells in pancreas ↑ Insulin sensitivity , anti-
inflammatory,  anti-atherogenic 
↑ in PWS compared to non-PWS obese, 
significant positive correlation with 
insulin sensitivity in PWS but not in 
obese controls 
(33) 
    ↑ in PWS compared to obese controls 
but ↓ in PWS compared to lean, no 
correlation with insulin sensitivity and 
anthropometric measurements 
(37) 
Visfatin Adipose tissue Pancreas, muscles, 
liver 
Associated with inflammation and 
insulin resistance. Increase with 
short sleep duration 
No data available  
PYY Duodenum Inhibitory 
Presynaptic receptor 
for NPY 
Induce satiety by stimulating 
POMC and inhibiting NPY 
resulting in dis-inhibition of α and 
β MSH 
↓ PYY (3-36) in PWS compared to 
healthy controls leading to delayed 
sense of fullness 
(14) 
   Reduce gastric emptying and gut 
transit time 
Delayed sense of fullness, overeating   
    ↑ in PWS compared to non-PWS obese, (61) 
    ↑ in PWS compared to obese controls 
but ↓ in PWS compared to lean. No 
correlation with insulin sensitivity and 
anthropometric measurements 
(37) 
Page 29 of 50 Pediatric Obesity
GLP-1; Glucagon-like peptide 1, AGRP; Agouti-related peptide, GH; growth hormone,  POMC; pro-opiomelanocortin, NPY; neuropeptide Y, 
NIDDM; non-insulin dependent diabetes mellitus,  PWS; Prader-Willi syndrome. 
Insulin Pancreas POMC and NPY 
neurons in arcuate 
nucleus 
Stimulate POMC and inhibit NPY 
neurons leading to stimulation of 
MCR4 receptor to induce satiety 
↓ in PWS leading to hyperphagia, and 
NIDDM in adulthood 
(61) 
Growth 
Hormone 
Anterior 
pituitary 
Muscles, Bones, 
adipose tissue 
Induces normal growth and 
energy metabolism 
Growth delay, altered metabolism and 
energy expenditure 
(24, 25) 
GLP-1 Intestine Pancreas Enhances insulin sensitivity  No difference at baseline, ↑ after GH 
replacement therapy 
(33) 
Thyroid 
hormones 
Thyroid gland Muscles, Bones, 
adipose tissue 
Regulate whole body metabolism ↓ in PWS resulting in altered metabolic 
rate and energy expenditure 
(38) 
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